Fifth Immunotherapy of Cancer Conference (ITOC5)

Starts:  Mar 19, 2018 3:00 AM (CET)
Ends:  Mar 21, 2018 3:00 AM (CET)

This program has already taken place.

The Cancer Drug Development Forum (CDDF) in collaboration with the Society for Immunotherapy of Cancer (SITC) had the great pleasure of inviting you to take part in the 5th Immunotherapy of Cancer Conference (ITOC5) – the leading International conference in Europe providing a global platform for translational research in the field of immuno-oncology.

The ITOC series of conferences has been the premier meeting for education, scientific exchange, and networking within the European cancer immunotherapy field.

It aimed at providing a forum for all professionals working in immunotherapy to discuss early clinical drug development and addressed the unique challenges of translational research.

The program focused on the latest challenges and innovations with a special emphasis on combination therapy, immuno-monitoring and biomarker development.

This conference, particularly addressed preclinical and clinical scientists, clinical investigators, postdoctoral fellows involved in cancer research, regulatory scientists, healthcare professionals and the pharmaceutical industry.

The program took place in Berlin, Germany on 19 – 21 March 2018.

SITC members qualified for discounted rates with a valid SITC member number. To find more information, please click here.

#2018
#Biomarkers
#ClinicalTrials
#BoneCancers
#BrainCancers
#BreastCancers
#ColorectalCancer
#GastrointestinalCancers
#GenitourinaryCancers
#HeadandNeckCancers
#HematologicMalignancies
#LungCancers
#SkinCancers
#Article
#InPersonEvent
#Collaboration
#CollaborativeEvent
#Adverse Events
#Cellular Therapies
#ImmuneCheckpointInhibitors
#Toxicities
#Clinician
#Oncologist
#Researcher

Location

Mercure Hotel Moa Berlin
Stephanstraße 41
Berlin, 10559